This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Sofosbuvir for the treatment of patients with genotype 4 hepatitis C: a review of the clinical efficacy, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014
Sofosbuvir in combination with peginterferon and ribavirin is recommended for treatment of naïve-patients, who are eligible and not eligible to receive interferon, as well as those who are peginterferon/ribavirin non-responders. There was no evidence of comparative clinical efficacy and cost-effectiveness of sofosbuvir for the treatment of HCV genotype 4 identified.
Subject indexing assigned by CRD
Genotype; Hepacivirus; Hepatitis Cs
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published